Varsha Tulpule1, Gareth J Morrison1, Mary Falcone2, David I Quinn1,2, Amir Goldkorn3,4,5. 1. Division of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 2. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 3. Division of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. agoldkor@med.usc.edu. 4. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. agoldkor@med.usc.edu. 5. Department of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. agoldkor@med.usc.edu.
Abstract
PURPOSE OF REVIEW: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer. RECENT FINDINGS: To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.
PURPOSE OF REVIEW: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer. RECENT FINDINGS: To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.
Authors: Howard I Scher; Glenn Heller; Arturo Molina; Gerhardt Attard; Daniel C Danila; Xiaoyu Jia; Weimin Peng; Shahneen K Sandhu; David Olmos; Ruth Riisnaes; Robert McCormack; Tomasz Burzykowski; Thian Kheoh; Martin Fleisher; Marc Buyse; Johann S de Bono Journal: J Clin Oncol Date: 2015-03-23 Impact factor: 44.544
Authors: Benjamin J Hindson; Kevin D Ness; Donald A Masquelier; Phillip Belgrader; Nicholas J Heredia; Anthony J Makarewicz; Isaac J Bright; Michael Y Lucero; Amy L Hiddessen; Tina C Legler; Tyler K Kitano; Michael R Hodel; Jonathan F Petersen; Paul W Wyatt; Erin R Steenblock; Pallavi H Shah; Luc J Bousse; Camille B Troup; Jeffrey C Mellen; Dean K Wittmann; Nicholas G Erndt; Thomas H Cauley; Ryan T Koehler; Austin P So; Simant Dube; Klint A Rose; Luz Montesclaros; Shenglong Wang; David P Stumbo; Shawn P Hodges; Steven Romine; Fred P Milanovich; Helen E White; John F Regan; George A Karlin-Neumann; Christopher M Hindson; Serge Saxonov; Bill W Colston Journal: Anal Chem Date: 2011-10-28 Impact factor: 6.986
Authors: Amir Goldkorn; Catherine Tangen; Melissa Plets; Gareth J Morrison; Alexander Cunha; Tong Xu; Jacek K Pinski; Sue A Ingles; Timothy Triche; Andrea L Harzstark; Manish Kohli; Gary R MacVicar; Daniel A Vaena; Anthony W Crispino; David J McConkey; Primo N Lara; Maha H A Hussain; David I Quinn; Nicholas J Vogelzang; Ian Murchie Thompson; Neeraj Agarwal Journal: Clin Cancer Res Date: 2021-01-26 Impact factor: 13.801
Authors: V Conteduca; D Wetterskog; M T A Sharabiani; E Grande; M P Fernandez-Perez; A Jayaram; S Salvi; D Castellano; A Romanel; C Lolli; V Casadio; G Gurioli; D Amadori; A Font; S Vazquez-Estevez; A González Del Alba; B Mellado; O Fernandez-Calvo; M J Méndez-Vidal; M A Climent; I Duran; E Gallardo; A Rodriguez; C Santander; M I Sáez; J Puente; D Gasi Tandefelt; A Wingate; D Dearnaley; F Demichelis; U De Giorgi; E Gonzalez-Billalabeitia; G Attard Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Romina Silva; Bruce Moran; Anne-Marie Baird; Colm J O'Rourke; Stephen P Finn; Ray McDermott; William Watson; William M Gallagher; Donal J Brennan; Antoinette S Perry Journal: Clin Epigenetics Date: 2021-08-28 Impact factor: 6.551